Comparison Overview
ERLEADA® for HCP
ERLEADA® for HCP
N/A
Last Update: 27/11/2025
ERLEADA® (apalutamide) is an androgen receptor inhibitor indicated for the treatment of patients with: • Metastatic castration-sensitive prostate cancer (mCSPC) • Non-metastatic castration-resistant prostate cancer (nmCRPC) This information is for US healthcare profess...
UCB
Allée de la Recherche, 60, Brussels, BE
Last Update: 14/06/2026
At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful sol...
Compliance Ranges Comparison
ERLEADA® for HCP
UCB
Benchmark & Cyber Underwriting Signals
Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)
No incidents recorded for ERLEADA® for HCP in 2026.
Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)
No incidents recorded for UCB in 2026.
Incident History - ERLEADA® for HCP (X = Date, Y = Severity)
ERLEADA® for HCP cyber incidents detection timeline including parent company and subsidiaries.
Incident History - UCB (X = Date, Y = Severity)
UCB cyber incidents detection timeline including parent company and subsidiaries.
Notable Incidents
ERLEADA® for HCP
UCB
FAQ
Latest Global CVEs
Pronetiqs IntraVUE versions 3.2.1a14 and prior have an inadequate encryption strength vulnerability which could allow an attacker to steal admin credentials via weak hash or a pass-the-hash attack.
Pronetiqs IntraVUE versions 3.2.1a14 and prior have an exposure of sensitive system information to an unauthorized control sphere vulnerability which could allow for asset discovery by unauthenticated users.
Pronetiqs IntraVUE versions 3.2.1a14 and prior have an unintended proxy or intermediary vulnerability which could allow an attacker to use an active proxy, which would bypass OT segmentation.
Pronetiqs IntraVUE Versions 3.2.1a14 and prior have a plaintext storage of a password vulnerability that could expose cleartext credentials through the API.
Pronetiqs IntraVUE versions 3.2.1a14 and prior have an exposure of sensitive system information to an unauthorized control sphere vulnerability which could expose the underlying host/share filesystem.